Clinical Trials · NCT03175211
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 20
- Start date
- Jun 2017
- Locations
- 1 site, Germany
- Primary endpoint
- [N (%)] of subjects with drug-related adverse events.